| Authors | Lee, A.L. Hill, C.J. McDonald, C.F. Holland, A.E |
|---|---|
| Type | Journal Article (Review) |
| Journal | Archives of physical medicine and rehabilitation |
| PubMed ID | 27320420 |
| Year of Publication | 2016 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/27320420 |
| DOI | http://dx.doi.org/10.1016/j.apmr.2016.05.017 |
| Abstract | OBJECTIVE: To examine the effect of pulmonary rehabilitation (PR) (exercise and education) or exercise training (ET) on exercise capacity, health-related quality of life (HRQOL), symptoms, frequency of exacerbations and mortality compared to no treatment in adults with bronchiectasis. DATA SOURCES: Computer-based databases were searched from their inception to February 2016. STUDY SELECTION: Randomized controlled trials of PR or ET versus no treatment in adults with bronchiectasis were included. DATA EXTRACTION: Two reviewers independently extracted data and assessed methodological quality using the Cochrane Risk of Bias tool. DATA SYNTHESIS: Four trials with 164 participants were included, with variable study quality. Supervised outpatient PR or ET of eight weeks improved incremental shuttle walk distance (weighted mean difference (WMD): 67m; 95% CI 52 to 82m) and disease-specific HRQOL (WMD -4.65, 95% CI -6.7 to -2.6 units) immediately following intervention, but these benefits were not sustained at six months. There was no effect on cough-related QOL (WMD 1.3, 95% CI -0.9 to 3.4 units) or psychological symptoms. PR commenced during an acute exacerbation and continued beyond discharge had no effect on exercise capacity or HRQOL. The frequency of exacerbations over 12 months reduced with outpatient ET (median 2 versus 1, p=0.013), but PR initiated during an exacerbation had no impact on exacerbation frequency or mortality. CONCLUSION: Short term improvements in exercise capacity and HRQOL were achieved with supervised PR and ET programs, but sustaining these benefits is challenging in people with bronchiectasis. The frequency of exacerbations over 12 months was reduced with ET only |
http://www.ibas.org.au/what-we-do/publications/3872822
Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....
RESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE
The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...
Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.
HONORING EXCELLENCE IN RESEARCH
Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.
Grants Success: The Institute for Breathing and Sleep (IBAS) has received two research grants from the Austin Medical Research Foundation (AMRF) for 2025. Congratulations to Dr Charissa Zaga and Dr Catherine Hill from IBAS.
Congratulations to Professor David Berlowitz, Dr Marnie Graco, and Dr Nicole Sheers who were recognised by Motor Neurone Disease (MND) Australia at a Parliament House event sponsored by the Parliamentary Friends of MND in Canberra last week.
© 2025 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
